Sponsored by
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
M&A
2022 M&A Outlook: Deal Market Expected to Continue Hot Pace
Buyers will hunt for targets that improve their talent bases, supply chains, and sustainability strategies.
By
Vincent Ryan
| January 20, 2022
Read More
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Sign Up
Sponsored by
Pfizer
People
CFOs On the Move: Week Ending November 19
Workday, Canopy Growth, Poshmark, Continental AG, CBE Companies, MultiPlan, CMC Materials, Omnipresent, Pfizer
By
Vincent Ryan
| November 19, 2021
Read More
People
Frank D’Amelio to Step Down as Pfizer CFO
During his 14-year tenure, D'Amelio played a key role in transforming Pfizer into "an industry leading, science-based biopharmaceutical company."
By
Matthew Heller
| November 18, 2021
Read More
Risk & Compliance
Merck Drops Out of COVID-19 Vaccine Race
Merck's announcement that it is shelving its two vaccine candidates "marks a shocking setback for one of the most storied vaccine makers."
By
Matthew Heller
| January 25, 2021
Read More
Risk & Compliance
Early Analysis Shows Pfizer COVID-19 Vaccine 90% Effective
The company said 50 million doses of its two-shot vaccine could be available globally by the end of 2020.
By
Lauren Muskett
| November 9, 2020
Read More
Risk & Compliance
Pfizer, BioNTech to Supply U.S. Government Up to 600M Doses of Coronavirus Vaccine
The initial 100 million doses ordered is valued at $1.95 billion.
By
Lauren Muskett
| July 22, 2020
Read More
M&A
Pfizer and Mylan to Combine Off-Patent Drugs Businesses
The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
By
Lauren Muskett
| July 29, 2019
Read More
Financial Performance
Pfizer Beats Estimates on Strength in Key Drugs
Sales from Pfizer's innovative health division were particularly strong in the second quarter, with anti-smoking drug Chantix up 8% to $8.2 billion.
By
Matthew Heller
| July 31, 2018
Read More
Strategy
Pfizer to Split Into Three Units
The company also announced it would defer drug price hikes, following pressure from President Donald Trump.
By
William Sprouse
| July 11, 2018
Read More
Tax
Pfizer Q4 Profit Surges to $12B But Shares Fall
The 3% drop in the share price appears to reflect the company's estimate of a 2018 tax rate of 17%, which is higher than investors anticipated.
By
Matthew Heller
| January 30, 2018
Read More
Financial Performance
Generic Competition Hits Pfizer’s Q2 Sales
The drug maker cites headwinds from losses of market exclusivity for the 14% drop in Essential Health revenues.
By
Matthew Heller
| August 2, 2017
Read More
Training
What Makes for a Public-Company CFO?
Five top finance chiefs tell how they got where they are, and what their potential successors need to do.
By
David McCann
| May 31, 2017
Read More
Strategy
Pfizer Makes Cancer Play With Medivation Deal
The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
By
Matthew Heller
| August 22, 2016
Read More
Risk & Compliance
Ex-Pfizer Employee Accused of Insider Trading
Michael Maciocio allegedly misused confidential information about potential Pfizer deals to make trades himself and tip off a stockbroker friend.
By
Matthew Heller
| June 3, 2016
Read More
Strategy
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
By
Katie Kuehner-Hebert
| May 16, 2016
Read More
Corporate Finance
Finance Roundup for Executives
Be informed, get involved, and shape the world through finance. Read CFO.com's most recent headlines and standout stories.
By
Kerry Maruna
| April 7, 2016
Read More
Next
